Adnan Majid, MD
Pulmonary Disease · Boston, MANPI 1790797561
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (33.0%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Olympus Latin America, Inc. at 28.4% of the total. Among pulmonary disease clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 534 payments — averaging $656.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Olympus Latin America, Inc.$100K
- Pinnacle Biologics, Inc$62K
- Olympus Corporation Of The Americas$58K
- US Endoscopy$21K
- Cook Incorporated$20K
- Boston Scientific$20K
- plus $70K from 28 others
Across 34 payments — averaging $12,855 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Galvanize Therapeutics, Inc$236K
- Pneumrx, Inc$80K
- Gyrus ACMI, Inc.$52K
- Pulmonx Corporation$51K
- BD$9K
- Bard Peripheral Vascular, Inc.$7K
- plus $3K from 2 others
What the payments were for
- Consulting fees$70,20020%
- Speaking & faculty fees$105,75030%
- Grants$5,5002%
- Travel & lodging$41,37412%
- Food & beverage$11,7523%
- Education$115,73833%
- Gifts$3010%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Olympus Latin America, Inc. | 164 | $99,716 |
| Pinnacle Biologics, Inc | 65 | $61,643 |
| Olympus Corporation Of The Americas | 82 | $58,455 |
| US Endoscopy | 4 | $20,800 |
| Cook Incorporated | 8 | $20,464 |
| Boston Scientific | 26 | $19,941 |
| Intuitive Surgical | 44 | $14,842 |
| Pulmonx Corporation | 28 | $13,882 |
| Johnson & Johnson | 14 | $12,488 |
| Olympus America Inc. | 12 | $6,367 |
| Medtronic | 21 | $6,207 |
| Olympus Medical Systems Corporation | 5 | $5,538 |
| Spiration, Inc. | 6 | $2,116 |
| Olympus Corporation | 7 | $1,463 |
| Veran Medical Technologies, Inc. | 4 | $1,408 |
| Gyrus ACMI, Inc. | 3 | $1,333 |
| Steris Corporation | 10 | $895 |
| Janssen Research & Development, LLC | 1 | $675 |
| Noah Medical Corporation | 5 | $532 |
| ERBE USA Inc | 5 | $521 |
| Serpex Medical Inc | 1 | $172 |
| Bard Peripheral Vascular, Inc. | 1 | $171 |
| Covidien LP | 3 | $154 |
| Philips North America LLC | 1 | $127 |
| AstraZeneca | 1 | $125 |
| Cook Medical LLC | 2 | $121 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $92 |
| Verona Pharma, Inc. | 1 | $82 |
| Rocket Medical LLC | 1 | $79 |
| Galvanize Therapeutics, Inc | 1 | $72 |
| Lumenis, Inc | 1 | $59 |
| Pfizer | 1 | $28 |
| Ambu Inc. | 1 | $24 |
| Merck | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Photofrin$59,850
- EVES EUS ULTRASOUND BRONCHOFIBERVIDEOSCOPE$45,528
- EVIS EXERA II ULTRASONIC BRONCHOFIBERVIDEOSCOPE$42,071
- Olympus EBUS Bronchoscopes$27,263
- TRUFREEZE$21,440
- Olympus Respiratory Accessories$19,731
- Olympus Capital Accessories$19,291
- EVIS EXERA III BRONCHOVIDEOSCOPE$18,826
- Blue Rhino$14,285
- Da Vinci Surgical System$13,815
- Olympus Bronchoscopes$13,131
- ZEPHYR ENDOBRONCHIAL VALVE$12,976
- Monarch Platform$12,259
- Spiration Valve System$9,900
- EBUS$8,800
- EVIS EXERA$6,600
- GENERAL PULMONARY$6,382
- Olympus Endoscopic Ultrasound Scopes$6,027
- ILLUMISITE$5,571
- EXALT Model D$5,501
How this compares
$350,614 in reported general payments places this provider in the 95th percentile of 482 pulmonary disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Boston
- Erik FolchBoston$543K
- Bartolome CelliBoston$536K
- Nicholas HillBoston$293K
- Harrison FarberBoston$190K
- Tufik AssadBoston$132K
- Anthony FaugnoBoston$132K
- Hyun KimBoston$117K
- George WashkoBoston$101K
- Aaron WaxmanBoston$88K
- Kelsey SackBoston$83K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.